Research
Hormonal
Semaglutide 2.4 mg/week leads to significant weight loss and improvement in cardiovascular risk factors (blood pressure, lipids, inflammation) in overweight or obese adults without diabetes.
Semaglutide 2.4 mg/week helps overweight or obese individuals lose an average of 9.4% of their body weight over 104 weeks, compared to less than 1% with placebo. This weight loss is associated with improvements in blood pressure, cholesterol, and inflammation markers, contributing to better cardiovascular health.
StrongSupportsVERY_HIGH confidence
Mean change in body weight over 104 weeks was -9.4% and -0.9% with semaglutide and placebo, respectively; estimated treatment difference (ETT) -8.5% (95% CI, -8.5 to -8.3). There was significant amelioration in blood pressure and plasma levels of lipids, glycated hemoglobin (HbA1c), and C- reactive protein (CRP).
Why this rating
Based on the SELECT trial, a large, randomized, placebo-controlled trial.
Source
Semaglutide: The First Anti-Obesity Agent Shown to Decrease Cardiovascular Events
Nasser Mikhail et al. · Annals of Cardiovascular Diseases · 2024
DOI 10.47739/2641-7731.cardiovasculardiseases.1036
narrative_review · n=17604Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide 2.4 mg/week significantly reduces major adverse cardiovascular events (MACE) in overweight or obese adults with preexisting cardiovascular disease but without diabetes.Strong
- Semaglutide 2.4 mg/week significantly reduces the incidence of new-onset type 2 diabetes and prediabetes in overweight or obese adults without diabetes.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →